This report examines how new technologies can emerge in the face of economic pressures that may affect the demand for nuclear imaging, and how healthcare reforms are impacting nuclear medicine. The advent of hybrid imaging has enabled PET/CT imaging to undergo explosive growth. However, this has been at the cost of an increased demand on struggling healthcare budgets. PET and SPECT imaging are well established techniques within nuclear imaging, and are the main focus of this report PET imaging uses Positron Emitting radioactive tracers with a short half life, to image metabolically active organs PET combined with CT allows precise anatomical imaging of the body, identifying diseased areas depending upon the tracer used PET/CT is most often used for cancer diagnosis PET/MRI is a new technique that was introduced to reduce patient exposure to radiation PET only systems are now generally considered obsolete, due to the superior imaging quality of PET/CT

The Brazilian (South American) nuclear imaging market was dominated by GE Healthcare and Siemens Healthcare, which each accounted for 40% of the market share in terms of revenue in 2012, The population in Brazil is both rapidly expanding but also experiencing increases in diseases, such as cardiovascular disease, that are associated with an increased adoption of Western lifestyles. Increased access to cardiovascular imaging facilities will also increase access to SPECT-only systems.

Scope

• An overview of Nuclear Imaging, which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
• Annualized South America Nuclear Imaging market revenue and future forecasts from 2011 to 2013, forecast for 7 years to 2020.
• Investigation of current and future market competition for Nuclear Imaging.
• Insightful review of the key industry drivers, restraints and challenges as well as predicted impact of key events.
• Competitor assessment including device approval analysis and device sales forecasts.
• Marketed and pipeline product profiles covering efficiency, safety, clinical study details, device approvals, product positioning and device sales forecast.
• Analysis of unmet needs within the market and opportunities for future players.
• Technology trends evaluation to assess strength of pipeline.
• An overview of all devices in development including clinical study details, design and material selection considerations, efficacy reports, and device approval timelines.
• Company profiles including business description, financial overview and SWOT analysis.
• Coverage of key market players.
• Strategic assessment of the Nuclear Imaging sector through market impact analysis, future market scenario and company analysis.
• Direct quotes from Key Opinion Leaders (KOL) as well as doctors

Reasons to buy

• Understand the trends shaping and driving South America Nuclear Imaging market.
• Realize device preferences of physicians who have performed the tests already.
• Access market sizing, forecasts and quantified growth opportunities in South America Nuclear Imaging market through 2018.
• Quantify candidate patient populations to better design product pricing & launch plans.
• Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape.
• Perform benchmarking analysis of growth opportunities against currently marketed products.
• Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
• Take a comprehensive look at the market’s device pipeline and identify promising, paradigm-shifting products.
• Create an effective counter-strategy to gain a competitive advantage against those currently in the market.
• Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for growth.
• What’s the next big thing in South America Nuclear Imaging market landscape? Identify, understand and capitalize.

Table of Contents

1 Table of Contents 6
1.1 List of Tables 12
1.2 List of Figures 15

2 Introduction 16
2.1 Catalyst 16
2.2 Related Reports 16

3 Industry Overview 17
3.1 Nuclear Imaging Techniques 17
3.1.1 Positron Emission Tomography 17
3.1.2 Single-Photon Emission Computed Tomography 19
3.1.3 Planar Scintigraphy 19
3.1.4 Hybrid Imaging 20
3.2 Clinical Applications of Nuclear Imaging Technology 25
3.2.1 Cancer 25
3.2.2 Cardiology 27
3.2.3 Neurology 29
3.2.4 Infection and Inflammation 31
3.3 Advantages and Disadvantages of Nuclear Imaging Technologies 34
3.4 Market Access 35
3.4.1 Product Life Cycle 35
3.4.2 Purchasing Decisions 37
3.4.3 Equipment Leasing 43
3.4.4 Replacement of PET/CT by PET/MRI 43
3.5 Reimbursement 48
3.5.1 Overview 48
3.5.2 Brazil 49
3.6 Procedure Trends 50
3.6.1 Brazil 50
3.7 Regulatory Issues/Recalls 53
3.8 M&As and Key Partnerships 53
3.9 Economic Impact 56
3.9.1 Europe 59

4 Unmet Needs 60
4.1 Overview 60
4.2 Improved Reimbursement for New Techniques 60
4.3 Lack of Binding Clinical Guidelines 64
4.4 Patient Comfort and Convenience 64
4.5 Reducing Radiation Exposure 65
4.6 Improved Scanner Performance 67
4.7 Image Processing Software Improvements 68
4.8 Increased Risk of Artifacts in Hybrid Images 70
4.9 Demand for New Radiotracers 71
4.10 Improved Clinical Input into the Design Process 73

5 Market Opportunity Analysis 74
5.1 Cheaper, Simpler Nuclear Imaging Devices 74
5.2 SPECT/CT in Developing Countries 74
5.3 Increased Demand for Teleradiology Services 76

6 Market Drivers and Barriers 78
6.1 Driver: Aging Population and Increasing Disease Prevalence 78
6.2 Driver: Referring Physician Awareness 79
6.3 Driver: Defensive medicine 80
6.4 Driver: Patient Awareness 82
6.5 Driver: Self-Referral 82
6.6 Driver: New Imaging Agents 83
6.7 Driver: Increasing Demand for Cancer Diagnostic Tests 83
6.8 Driver: Companion Diagnostic Testing 84
6.9 Barrier: Comparative Effectiveness Research 85
6.10 Barrier: Reimbursement Legislation 87
6.11 Barrier: Increasing Demand for Nuclear Imaging in Developing Markets 87
6.12 Barrier: Insurance Company Lobbying to Reduce Unnecessary Imaging 89
6.13 Barrier: Greater Payer Scrutiny of EMRs 89
6.14 Barrier: Increased Use of Appropriateness Criteria 90
6.15 Barrier: Practice Guidelines to Reduce Unnecessary Procedures 92
6.16 Barrier: Imaging Facility Accreditation 92
6.17 Barrier: Loss of Nuclear Medicine Skills 93
6.18 Barrier: High Cost of Instruments and Reagents 94
6.19 Barrier: Radiopharmaceutical Cost and Supply Difficulties 95
6.20 Barrier: Hospital Consolidation 98

7 Competitive Assessment 99
7.1 Overview 99
7.2 Dedicated PET Systems 99
7.2.1 Overview 99
7.2.2 Product Profile 100
7.2.3 SWOT Analysis 101
7.3 PET/CT Systems 101
7.3.1 Overview 101
7.3.2 Product Profiles 102
7.3.3 SWOT Analysis 104
7.4 PET/MRI Systems 104
7.4.1 Overview 104
7.4.2 Product Profile 106
7.4.3 SWOT Analysis 107
7.5 Dedicated SPECT Systems 107
7.5.1 Overview 107
7.5.2 Product Profile 108
7.5.3 SWOT Analysis 110
7.6 SPECT/CT Systems 110
7.6.1 Overview 110
7.6.2 Product Profile 112
7.6.3 SWOT Analysis 113
7.7 PET/Ultrasound and SPECT/Ultrasound Systems 113
7.7.1 Overview 113
7.7.2 Product Profile 114
7.7.3 SWOT Analysis 114

8 Pipeline Assessment 115
8.1 Overview 115
8.2 Pipeline by Phases in Development 116
8.3 Product Profiles 116
8.3.1 Brain Biosciences CerePET 116
8.3.2 ECORAD Dual Modality Imager 118
8.3.3 FMI Technologies ScintiStar PET/CT 119
8.3.4 IntraMedical Imaging Marginator Beta Camera 121
8.3.5 INSERT SPECT/MRI 122
8.3.6 Nucare/Zecotek Photonics New Generation PET Scanning Device 125
8.3.7 Philips Healthcare PET Alpha Ring Detector 126
8.3.8 Photo Diagnostic Systems NeuroPET/CT 127
8.3.9 SynchroPET Breast PET/MRI 128
8.3.10 SynchroPET Wrist Scanner 129
8.3.11 SurgicEye SPECT Hybrid 130

9 Clinical Trials to Watch 132
9.1 Overview 132
9.2 Clinical Trial Profiles 132

10 Current and Future Players 135
10.1 Overview 135
10.2 Trends in Corporate Strategy 135
10.3 Company Profiles 136
10.3.1 DDD-Diagnostic 136
10.3.2 Digirad 138
10.3.3 GE Healthcare 142
10.3.4 GVI Medical Devices 147
10.3.5 Mediso Medical Imaging Systems 150
10.3.6 NeuroLogica 152
10.3.7 Neusoft Medical Systems 154
10.3.8 NuCare Medical Systems 157
10.3.9 Oncovision 159
10.3.10 Philips Healthcare 161
10.3.11 Shimadzu 168
10.3.12 Siemens Healthcare 173
10.3.13 SurgicEye 179
10.3.14 Toshiba Medical 182
10.3.15 Other Companies 187

11 Market Outlooks 190
11.1 Company Market Share Analysis 190
11.2 By Geography 190
11.2.1 Brazil 191

12 Appendix 195
12.1 Abbreviations 195
12.2 Bibliography 199
12.3 Methodology 228
12.3.1 Overview 228
12.3.2 Coverage 228
12.3.3 Secondary Research 228
12.4 Physicians and Specialists Included in This Study 230
12.5 Primary Research 232
12.5.1 Primary Research - Key Opinion Leader Interviews 232
12.5.2 Expert Panel Validation 232
12.5.3 Stakeholder Survey 233
12.6 Forecasting Methodology 235
12.7 About the Authors 236
12.7.1 Andrew Thompson, PhD, Senior Analyst 236
12.7.2 Priya Radhakrishnan, MBA, Director, Medical Devices 236
12.7.3 Bonnie Bain, PhD, Global Head of Healthcare 237
12.8 About GlobalData 238
12.9 Disclaimer 238

List of Tables

Table 1: Applications of Nuclear Imaging 25
Table 2: FDG-PET Diagnostic Accuracy for Specific Cancers 26
Table 3: Potential Clinical Benefits of Hybrid Nuclear Imaging in Cardiology 29
Table 4: Applications of PET Imaging in Non-Cancer Neurology 30
Table 5: Applications of SPECT Imaging in Non-Cancer Neurology 30
Table 6: Characteristics of SPECT, PET, Ultrasound, CT, and MRI 35
Table 7: The Age of Canada's Hospital-Based Medical Technology Inventories, Relative to ECCREI Rules, 2009 36
Table 8: Nuclear Imaging Trends in Brazil, 2012-2020 52
Table 9: Recent Device Recalls in the Nuclear Imaging Market 53
Table 10: Recent Key Events in the Nuclear Imaging Market 55
Table 11: Nuclear Imaging Market Drivers and Barriers 78
Table 12: Duplicate Diagnostic Test Incidence in France, Germany, UK, and US 90
Table 13: Dedicated PET Scanners 100
Table 14: Dedicated PET SWOT Analysis 101
Table 15: PET/CT Scanners 102
Table 16: PET/CT SWOT Analysis 104
Table 17: PET/MRI Systems 106
Table 18: PET/MRI SWOT Analysis 107
Table 19: Dedicated SPECT Systems 108
Table 20: Dedicated SPECT SWOT Analysis 110
Table 21: SPECT/CT Systems 112
Table 22: SPECT/CT SWOT Analysis 113
Table 23: SPECT-Ultrasound Systems 114
Table 24: SPECT/Ultrasound SWOT Analysis 114
Table 25: Nuclear Imaging Pipeline, 2014 116
Table 26: CerePET SWOT Analysis 118
Table 27: ECORAD Dual Modality Imager SWOT Analysis 119
Table 28: ScintiStar PET/CT SWOT Analysis 121
Table 29: Marginator SWOT Analysis 122
Table 30: INSERT SPECT-MRI SWOT Analysis 125
Table 31: Nucare/Zecotek Photonics New Generation PET Scanning Device SWOT Analysis 126
Table 32: PET Alpha Ring Detector 127
Table 33: NeuroPET/CT Scanner SWOT Analysis 128
Table 34: SynchroPET Breast PET/MRI SWOT Analysis 129
Table 35: SynchroPET Wrist Scanner 130
Table 36: SurgicEye SPECT/Ultrasound device SWOT Analysis 131
Table 37: Key Clinical Trials 133
Table 38: Company Profile - DDD-Diagnostic 136
Table 39: DDD-Diagnostic SWOT Analysis 138
Table 40: Company Profile - Digirad 139
Table 41: Digirad SWOT Analysis 142
Table 42: Company Profile - GE Healthcare 143
Table 43: GE Healthcare Product Portfolio 144
Table 44: GE Healthcare SWOT Analysis 147
Table 45: Company Profile - GVI Medical Devices 148
Table 46: GVI Medical Devices SWOT Analysis 149
Table 47: Company Profile - Mediso Medical Imaging Systems 150
Table 48: Mediso Medical Imaging Systems SWOT Analysis 151
Table 49: Company Profile - Neurologica 152
Table 50: Neurologica SWOT Analysis 154
Table 51: Company Profile - Neusoft Medical Systems 155
Table 52: Neusoft Medical Systems SWOT Analysis 157
Table 53: Company Profile - NuCare Medical Systems 158
Table 54: Nucare Medical Systems SWOT Analysis 159
Table 55: Company Profile - Oncovision 160
Table 56: Oncovision SWOT Analysis 161
Table 57: Company Profile - Philips Healthcare 162
Table 58: Philips Healthcare SWOT Analysis 168
Table 59: Company Profile - Shimadzu 169
Table 60: Shimadzu SWOT Analysis 173
Table 61: Company Profile - Siemens Healthcare 174
Table 62: Siemens Healthcare SWOT Analysis 179
Table 63: Company Profile - SurgicEye 180
Table 64: SurgicEye SWOT Analysis 182
Table 65: Company Profile - Toshiba Medical 183
Table 66: Toshiba Medical SWOT Analysis 186
Table 67: Other Companies in the Nuclear Imaging Market, 2014 187
Table 68: South America Sales of PET and SPECT Imaging Systems, 2012-2020 191
Table 69: Brazil Market Value Forecast by Market Sub-segment (2012-2020) 192
Table 70: Primary Research Summary 233
Table 71: Primary Research Participants Affiliation 234

List of Figures

Figure 1: Cyclotron Distribution in 10 Countries 18
Figure 2: Localization of Tumor in Chest Cavity by PET, CT, and PET/CT 22
Figure 3: Mutually Beneficial Effects of PET/MRI Imaging 24
Figure 4: Nuclear Imaging Trends in Brazil, 2012-2020 52
Figure 5: Total Medicare Expenditures for Imaging Services Paid Under the Physician Fee Schedule, 2000-2006 57
Figure 6: Imaging Utilization Rates (Number of Outpatient Visits with MRI/CT per 1,000 Persons), by Year in the US 79
Figure 7: Brazil Company Market Shares for Nuclear Imaging Equipment (2012) 190
Figure 8: South America Sales of PET and SPECT Imaging Systems, 2012-2020 191
Figure 9: Brazil Market Value Forecast by Market Sub segment (2012-2020) 192
Figure 10: Primary Research Summary 233
Figure 11: Primary Research Participants Affiliation 234